BMS achieves rare next-generation checkpoint win with Phase III LAG3 data

BMS continued its successful run in checkpoint inhibitors with the first example of a Phase III survival benefit among mAbs against next-generation targets, but it will be hard to determine where the therapy may fit into the market until quantitative data are available.

Bristol Myers Squibb Co. (NYSE:BMY) reported that anti-LAG3 mAb relatlimab plus its PD-1 inhibitor Opdivo nivolumab met the primary endpoint of improving progression-free survival as first-line therapy for metastatic or unresectable melanoma over Opdivo alone in the Phase II/III RELATIVITY-047 study...